Zobrazeno 1 - 2
of 2
pro vyhledávání: '"E J M, Kooijman"'
Autor:
N. Stergiou, T. E. Wuensche, M. Schreurs, I. Mes, M. Verlaan, E. J. M. Kooijman, A. D. Windhorst, L. Helboe, S. Vergo, S. Christensen, A. A. Asuni, A. Jensen, G. A. M. S. Van Dongen, B. Bang-Andersen, D. J. Vugts, W. Beaino
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging, 50(5), 1306-1317. Springer Verlag
Stergiou, N, Wuensche, T E, Schreurs, M, Mes, I, Verlaan, M, Kooijman, E J M, Windhorst, A D, Helboe, L, Vergo, S, Christensen, S, Asuni, A A, Jensen, A, van Dongen, G A M S, Bang-Andersen, B, Vugts, D J & Beaino, W 2023, ' Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 5, pp. 1306-1317 . https://doi.org/10.1007/s00259-023-06109-3
Stergiou, N, Wuensche, T E, Schreurs, M, Mes, I, Verlaan, M, Kooijman, E J M, Windhorst, A D, Helboe, L, Vergo, S, Christensen, S, Asuni, A A, Jensen, A, van Dongen, G A M S, Bang-Andersen, B, Vugts, D J & Beaino, W 2023, ' Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 5, pp. 1306-1317 . https://doi.org/10.1007/s00259-023-06109-3
Purpose The recent conditional FDA approval of Aducanumab (Adu) for treating Alzheimer’s disease (AD) and the continued discussions around that decision have increased interest in immunotherapy for AD and other brain diseases. Reliable techniques f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d269ebb8a676eb2d9dd830aa5a138c8
https://doi.org/10.1007/s00259-023-06109-3
https://doi.org/10.1007/s00259-023-06109-3
Autor:
A, Metaxas, R, Willems, E J M, Kooijman, V A, Renjaän, P J, Klein, A D, Windhorst, L Ver, Donck, J E, Leysen, B N M van, Berckel
Publikováno v:
Journal of neuroscience research. 92(11)
Although both the onset of schizophrenia and human phencyclidine (PCP) abuse typically present within the interval from adolescence to early adulthood, the majority of preclinical research employing the PCP model of schizophrenia has been conducted o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2c721a07b75a7e771bc25ed680801c3c
https://pubmed.ncbi.nlm.nih.gov/24953757
https://pubmed.ncbi.nlm.nih.gov/24953757